Identification | More | [Name]
Memantine hydrochloride | [CAS]
41100-52-1 | [Synonyms]
1,3-Dimethyl-5-aminoadamantane hydrochloride 1,3-DIMETHYLAMINOADAMANTANE HYDROCHLORIDE 1-AMINO-3,4-DIMETHYLADAMANTANE HYDROCHLORIDE 1-AMINO-3,5-DIMETHYLADAMANTANE HCL 1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE 3,5-DIMETHYL-1-ADAMANTANAMINE 3,5-DIMETHYL-1-ADAMANTANAMINE HYDROCHLORIDE 3,5-DIMETHYL-1-AMINOADAMANTANE HCL 3,5-dimethyl-1-aminoadamantane hydrochloride 3,5-DIMETHYLAMANTADINE HYDROCHLORIDE 3,5-DIMETHYLTRICYCLO-[3,3,1,13,7]DECAN-1-AMINE 3,5-DIMETHYL-TRICYCLO[3.3.1.13,7]DECAN-1-AMINE HYDROCHLORIDE AKATINOL D-145 DMAA LABOTEST-BB LT00233220 MEMANTINE HCL TIMTEC-BB SBB003390 Memantin MemantinHCl | [EINECS(EC#)]
255-219-6 | [Molecular Formula]
C12H22ClN | [MDL Number]
MFCD00214336 | [Molecular Weight]
215.76 | [MOL File]
41100-52-1.mol |
Chemical Properties | Back Directory | [Appearance]
Crystalline Solid | [Melting point ]
292 °C | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
Soluble in Water (up to 20 mg/ml) | [form ]
Fine Powder | [color ]
White | [Water Solubility ]
Soluble in water (100mM) | [Usage]
Used as an antiparkinsonian and antispasmodic | [Merck ]
5806 | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in distilled water may be stored at -20°C for up to 2 months. | [CAS DataBase Reference]
41100-52-1(CAS DataBase Reference) |
Safety Data | Back Directory | [Safety Statements ]
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
3
| [HazardClass ]
IRRITANT | [HS Code ]
29213000 |
Questions And Answer | Back Directory | [Description]
Memantine HCl is the HCl form of Memantine. Memantine is a well- known neuroprotective drug used for the treatment of Alzheimer’s disease. It is believed to be the first neuroprotective drug that has achieve clinical approval by US FDA as well as European. The development of Alzheimer’s disease involves the misfolded mutant proteins such as β-amyloid peptide (Aβ, particularly Aβ1−42). These misfolded mutant protein can increase the NMDA response and further cause severe excitotoxicity. Memantine suppresses this process through acting as the antagonist of the N-methyl-d- aspartate-sensitive glutamate receptor (NMDARs). Memantine is also under investigation as a potential treatment for other kind of neurodegenerative disorders such as HIV-associated dementia, neuropathic pain, glaucoma, depression, Huntington’s disease, ALS and movement disorders, among other.
| [References]
Reisberg, Barry, et al. New England Journal of Medicine 348.14 (2003): 1333-1341.
Lipton, Stuart A. Nature reviews Drug discovery 5.2 (2006): 160-170.
|
Hazard Information | Back Directory | [Chemical Properties]
Crystalline Solid | [Application]
Memantine HCl has been used:- as a media
supplement to serve as a control to study the neuroprotective effects of
erythropoietin in N-methyl-D-aspartate receptor-induced toxicity.
- to intraperitoneally inject experimental animal to study its effect on traumatic injury.
- as a test compound to determine the dynamic range and selectivity of retinal pigment epithelium tissue penetration.
| [Uses]
Anti Alzheimer's | [Uses]
Antiparkinsonian;Dopaminergic agonist | [Uses]
Used as an antiparkinsonian and antispasmodic | [Definition]
ChEBI: A hydrochloride obtained by reaction of memantine with one equivalent of hydrochloric acid. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. | [Brand name]
Namenda(Forest). | [General Description]
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Memantine Hydrochloride is a drug used for treating the Alzheimer′s disease by means of reducing abnormal activity in the brain. It can help patients suffering from dementia as it assists them to think more clearly and perform their chores with ease. | [Biochem/physiol Actions]
Memantine is effective against Alzheimer′s disease and Parkinson′s disease. It is also useful in treating epilepsy, motor neurone disease and trauma. | [Synthesis]
Memantine (XV) or 1-amino-
3,5-dimethyladamantane hydrochloride was first synthesized
by Lilly as an anti-diabetic agent but was ineffective in
lowering blood sugar. Several syntheses have been
detailed in the literature. However the simplest
synthesis of the drug was done in one step from the
commercially available 3,5-dimethyl adamantine (122).
Treatment of 122 with nitrogen trichloride (CAUTION: very
explosive gas!) in the presence of aluminum trichloride (ratio
of 1.5:1.2) gave the desired amino adamantine in 86% yield.
However, a much safer alternative has been reported by Lilly
scientists. Heating the commercially available 3,5-dimethyladamantane 122 in bromine gave the bromo
derivative 123 (86%) which was then reacted with sulfuric
acid in acetonitrile to provide quantitatively acetyl amino
derivative 124 after aqueous workup. Hydrolysis of the
acetyl group was done by heating 124 with sodium
hydroxide in diethylene glycol to give 1-amino -3,5-
adamantane (96%), which was then made into the
hydrochloride salt in ether and recrystallized from ether and
alcohol mixture to provide the final product memantine
hydrochoride XV. | [storage]
Room temperature |
|
|